Aurobindo Pharma in focus on launch of generic version of Sensipar tablets in US
Aurobindo Pharma's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets.
New Delhi: Drug maker Aurobindo Pharma Limited recently announced the launch of Cinacalcet Hydrochloride Tablets (30mg, 60mg, and 90mg) at risk in the US market in accordance with the terms of a settlement agreement with Amgen Inc.
Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets.
Also Read: Aurobindo Pharma, Dr Reddys, Torrent Pharma, Mylan cannot sell generic Gilenya patented by Novartis
Cinacalcet Hydrochloride tablets are indicated for the treatment of:
• Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on dialysis
• Hypercalcemia in adult patients with parathyroid carcinoma
• Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy
The product had an annual sale of approximately US$ 1,449 million for the twelve months ending May 2019 as per IQVIA.
Also Read: Aurobindo Pharma pulled up by USFDA for repeated CGMP failures
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd